Equities

4Basebio PLC

4BB:LSE

4Basebio PLC

Health CarePharmaceuticals and Biotechnology
  • Price (GBX)1,160.00
  • Today's Change15.00 / 1.31%
  • Shares traded2.19k
  • 1 Year change93.33%
  • Beta--
Data delayed at least 20 minutes, as of May 10 2024 16:19 BST.
More ▼

Financials data is unavailable for this security.

Inc stmt in GBPIncome statement in GBPView more

Year on year 4Basebio PLC's revenues fell -20.71% from 338.00k to 268.00k. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from a loss of 3.24m to a larger loss of 5.15m.
Gross margin80.51%
Net profit margin-1,772.60%
Operating margin-1,946.33%
Return on assets-52.42%
Return on equity-97.29%
Return on investment-60.21%
More ▼

Cash flow in GBPView more

In 2022, cash reserves at 4Basebio PLC fell by 5.24m. Cash Flow from Financing totalled 1.24m or 464.18% of revenues. In addition the company used 4.70m for operations while cash used for investing totalled 1.94m.
Cash flow per share-0.4611
Price/Cash flow per share--
Book value per share0.2769
Tangible book value per share0.0848
More ▼

Balance sheet in GBPView more

4Basebio PLC has a Debt to Total Capital ratio of 66.83%, a higher figure than the previous year's 11.68%.
Current ratio3.42
Quick ratio3.28
Total debt/total equity2.01
Total debt/total capital0.6683
More ▼
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.